Topical Rapamycin in treating Infantile Hemangiomas

Phase 3

Not yet recruiting

• Conditions: Congenital Hemangioma.; Hemangioma of skin and subcutaneous tissue; D18.01

• Registration Number: IRCT20191006045005N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Infantile Hemangioma in 1-12 month infants
Non complicated hemangiomas
Hemangiomas not in need of systemic or surgical treatments
Hemangiomas <= 3 cm

Exclusion Criteria

Complicated Hemangioma
Beta blocker adverse effects
Taking other medications interacting beta blockers
Cardiac,renal anomalies or asthma
History of hypoglycemia
Taking oral beta blocker for any reason

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
esion size. Timepoint: Aforementioned scores will be assessed at the beginning of treatment ( 0) and then each month for 3 month ( 1,2,3) during our treatment period. finally 1 and 3 month later after finished treatment as follow up ( 4,7). Method of measurement: Measured by ruler.;Clinical Score. Timepoint: Aforementioned scores will be assessed at the beginning of treatment ( 0) and then each month for 3 month ( 1,2,3) during our treatment period. finally 1 and 3 month later after finished treatment as follow up ( 4,7). Method of measurement: By this method we assess the pre-treatment and post-treatment size of hemangioma by getting photos of lesions ( by consent) , and then the score will be calculated as below: ( difference between pre and post hemangioma size*100/ pre size).